International Journal of Advanced Research in Biological Sciences
ISSN: 2348-8069
www.ijarbs.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijarbs Coden: IJARQG (USA) Volume 9, Issue 7 -2022

Review Article

DOI: http://dx.doi.org/10.22192/ijarbs.2022.09.07.011

H. pylori Infection in human Gastrointestinal Cancer Diagnosis and Treatment Control: A review

[1] Waqar Ahmad Khan, [2] Shahid Alishah
[1]Sarhad University of Science & Information Technology, Landi Akhun Ahmad, Hayatabad Link Peshawar Ring Rd., Garhi Sikandar Khan, Peshawar, Khyber Pakhtunkhwa, Pakistan
[2]Neurobiology lab, Gyeongsang National University South Korea, 501 Jinju-daero, Jinju, Gyeongsangnam-do, South Korea

Abstract

The diagnosis and management of upper gastroduodenal disease have seen a significant transformation in the 20 years after the first culture of HP. Infection with *Helicobacter pylori* plays a growing role in stomach malignancies, and its impact on other inflammation of the upper gastric tract is being investigated. The understanding of the pathogenesis of this infection has advanced greatly. There are effective antimicrobial treatments available, but there is still no perfect cure and the therapeutic indications are continually changing. When *H. pylori* infection is identified, the clinician evaluates the patient's clinical status to determine whether therapy is required. Usually, *H. pylori* removal is advised for the infection's treatment and prevention. *H. pylori* Infection in human Gastrointestinal Cancer Diagnosis and Treatment Control is the topic of this review.

Keywords: Bacteria *H. pylori*, Treatment, diagnosis, stomach, transmission, Prevention etc.

1. Introduction

The gram-negative, microaerophilic, spiral (helical), *Helicobacter pylori*, formerly known as *Campylobacter pylori*, is typically found in the stomach. [5] Its helical structure is assumed to have evolved to allow it to pierce the mucoid lining of the gastrointestinal and spread contagion. This shape gives rise to the genus name "helicobacter. [7,8] The Australian doctors Robin and Barry Marshall and Warren were the ones to discover the bacterium for the first time in 1982. [9-11] *Helicobacter pylori* (HP) has been related to extranodal marginal zone lymphoma B-cellof the mentioned organ, which is cancer of the mucosa-associated lymphoid tissue in the stomach, rectum, colon, oesophagus, or soft tissueround the eye. [13] and in the gut's lymphoid tissue (termed large diffuse lymphoma B-cell). [14] HP Infection typically has no symptoms, but it can occasionally result in gastritis (gastrointestinal disorder) in the gastrointestinal or first section of the intestine small. Additionally, the infection has been linked

to the emergence of some cancers. [15] Many researchers have hypothesised that *Helicobacter pylori* influences or protects against a variety of different disorders, but many of these connections are still debatable. [16-19]According to certain research, HP has an impact significant on the natural ecology of the stomach, such as the type of microorganisms that populate the stomach system. [15]

[18] According to other research, non-pathogenic Helicobacter Pylori strains may correct stomach acid secretion [20] and control hunger. [20] Over 50% of the world's population was thought to have HP in their upper intestinal tracts in 2015[6], with colon-izing (or infection) occurring more frequently in underdeveloped nations. [4] On the other hand, the frequency of HP colonization of the intestinal tract has decreased in various nations over the past few decades. [21]

Figure:1 *Helicobacter pylori* Infection



Figure:2 Natural of *Helicobacter pylori* Infection

2. *Helicobacter pylori* analysis tests

2.1 Nonedoscopic

1. Breath tests
2. Stool tests
3. Blood tests —

2.2 Endoscopic

1. Culture
2. Histology
3. Rapid Urease Testing
4. Polymerase Chain Reaction

3. *H. Pylori* risk factors

Consuming food or drink that has been contaminated with feces is most likely how H. pylori is disseminated. *HP* (the first part of the intestine small) The protective tissue lining the stomach becomes infected by the bacterium. This causes the immune system to get activated as well as the release of specific enzymes and toxins. Together, these elements may damage the stomach or duodenal cells directly or indirectly. H. pylori infection in children is uncommon in the United States and other industrialized nations, while it is more typical in adults. However, most children in nations with inadequate resources contract H. pylori before becoming 10 years old. [32]



Figure:3 Risk Factors for *H. pylori*

4. *H. pylori* symptoms

Most people with duodenitis or chronic gastritis don't exhibit any symptoms. However, some people experience more severe issues, such as duodenal or stomach ulcers.

The most typical ulcer symptoms include the following:

1. Pain in the upper stomach)
2. Bloating
3. Ulcers that bleed can cause a low blood count and fatigue
4. Feeling full after eating a small amount of food
5. Nausea
6. Appetite of lack
7. tar-colored stools



Figure: 4 Symptoms of Infection of *H. pylori*

5. Transmission of *H.pylori*

Although the precise mode of spread of *H. pylori* is unknown, it is contagious. [36] [37] The most likely methods of transmission are oral-oral (mouth-to-mouth contact, such as kissing) or fecal-oral. The bacteria have been separated from the faeces, saliva, and dental plaque of some affected individuals, which is consistent with these routes of transmission. According to research, stomach mucus spreads H. pylori more readily than saliva. [8] In developed countries, transmission primarily takes place within families, though it can also be contracted from the public in less developed nations. [38] The environment hygienic could aid in reducing the risk of *Helicobacter pylori* infection. *HP* may also be transferred orally through fecal matter through the consumption of water waste-tainted. [8]



Figure:5 Transmission of *H. pylori* Infection

6. *H. pylori* treatment

People with active duodenal ulcers, active stomach ulcers, or a history of ulcer peptic disease should receive treatment if they have an *Helicobacter Pylori*infection. A successful *Helicobacter Pylori*treatment can speed up the healing process, stop recurrent ulcers, and lower the risk of ulcer complications (like bleeding). H.P ulcer peptic disease can be controlled by the help of these medications which are the following [1,2].

6.1Medications

1. Aspirin,
2. ibuprofen,
3. naproxen,
4. Lansoprazole (Prevacid)
5. omeprazole (Prilosec)
6. pantoprazole (Protonix)
7. rabeprazole (AcipHex)
8. dexlansoprazole (Dexilant)
9. esomeprazole (Nexium)
10. (Flagyl) or clarithromycin
11. metronidazole (Flagyl) [33–35].



7. *H. pylori* therapy and Prevention infected patient

There is a clear need for innovative therapeutic approaches to stop or eradicate the microorganism from colonization people due to HP involvement as aforemost cause of several inflammations (especially malignancies) and its continually rising resistance antibiotic. [22] It has taken a lot of effort to create effective vaccines with the goal of offering a different approach to managing *H. pylori* infection and associated disorders. [23,24] In the Netherlands at least, the introduction of a prospective H. pylori vaccination for use in infants was found to be cost-effective for preventing stomach cancer and peptic ulcers. [25,26]The vaccination prevents kids from getting H. pylori infection), as of late 2019, there had been only one vaccine in a Phase I clinical trial and no advanced vaccine candidates.

Furthermore, major pharmaceutical firms have not currently placed a high priority on the development of a vaccination against HP. [27] According to studies, these therapies can lessen the infection's inflammation and some histopathological abnormalities when HP is completely removed from the stomach. The effectiveness of these treatments in treating the more severe histopathological abnormalities associated with H. pylori infections, such as gastric atrophy and metaplasia, both of which are precursors to gastric adenocarcinoma, is debatable, according to research. [28]Similar controversy exists regarding the prophylactic efficacy of antibiotic-based regimens against stomach cancer. These regimens did not seem to be able to stop the growth of this adenocarcinoma, according to a meta-analysis published in 2014 (i.e., a statistical study that integrates the outcomes of numerous randomized controlled trials). [29] However, two later prospective cohort studies on high-risk individuals in China and Taiwan indicated that the disease's incidence significantly decreased after the bacterium was eradicated. [16] as well as a meta-analysis of 24 studies conducted on people with various levels of illness risk that was also published in 2016. [30]

8. Prevention

In animal models, probiotics are being used to produce vaccines that could stop infections. reduction of risk factors such unhygienic living environment and poor socioeconomic level.

Literature Review

[39] According to data gathered, the prevalence of Helicobacter pylori resistance antibiotic is rising across the globe and is the primary factor impacting the effectiveness of existing therapy regimens. Reviewing recent information on Helicobacter pylori antibiotic resistance in various nations was our main goal. Antibiotic resistance among Helicobacter pylori strains to various antibiotics has grown globally. Different nations' therapeutic management may be impacted by such a situation.

[40] A significant advance in gastroenterology has been the identification of HP infection as the primary initiator of the majority of gastroduodenal disorders. Actually, it was discovered that Helicobacter pylori resistance to one of the employed antibiotics was the primary cause of failure (that is, clarithromycin). Other therapies have also been suggested, such as tetracycline, a fluoroquinolone for which resistance is a growing problem, and metronidazole, a medication for which resistance is a problem but to a lesser level.

[41]Helicobacter pylori, however, plays the most significant role in gastric carcinogen since the mucosa that is infected with HP is the source of the majority of stomach malignancies, as well as both intestinal type and diffuse type. Epidemiological research, trials on gerbils Mongolian, and prospective clinical studies have all demonstrated a link between HP infection and gastrointestinal cancer. Long-term outcome statistics are required despite the fact that treatment endoscopic for stomach malignance has been progressively rising.

[42]The overall success of treatments has decreased as a result of rising antimicrobial resistance, necessitating a reassessment of the methodology used to generate treatment guidelines as well as the requirement to adopt the concepts of antibiotic usage and antimicrobial stewardship. The triple therapy of clarithromycin, metronidazole, and levofloxacin must no longer be used as an emergency measure. Here, we talk about these changes and offer advice on how to evaluate and apply treatments that work when used empirically.

[43*Helicobacter pylori* is well known as the main cause of gastritis, duodenal ulcers, and gastric cancer, infecting over half of the world's population.

[44]This revised overview of the connection between Helicobacter pylori and Stomach cancer emphasises the substantial association between the organism and the disease's onset and proposes that eliminating the bacterial infection could serve

as a preventative tool against the emergence of this fatal malignancy. Currently, experts in the area including doctors and researchers stress how important it is to get H. pylori out of people's stomachs.

[45]As a result, there is a strong correlation among the risks of Helicobacter pylori infection and stomach cancer, making it essential to treat and prevent *H. pylori* infection. This consensus could offer recommendations for early Helicobacter pylori detection, diagnosis, and therapy to lower the incidence of stomach cancer in China.

[46]7-day triple therapy with a proton pump inhibitor, clarithromycin, metronidazole, or amoxicillin is the first line of treatment for this condition. In the event that treatment is unsuccessful, quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole, and a proton pump inhibitor) for two weeks is advised. All patients should be provided HP testing following eradication medication, but patients with noninvasive gastric cancer, ulcer disease, or mucosa-associated lymphoid tissue lymphoma must receive it. Testing following eradication shouldn't be carried out before 4 weeks have passed since the completion of therapy.

Result and Discussion

Over 50% of the world's population was thought to have HP in their upper gastrointestinal tracts in 2015, with developing nations having a higher prevalence of this infection (or colonization). However, the frequency of HP colonization of the gastrointestinal tract has decreased in many nations over the past few decades. Infection with HP typically has no symptoms, although it can occasionally result in (gastrointestinal Disorder) or ulcers in the intestinal or first section of the small intestine. Additionally, the infection has been linked to the emergence of several malignancies. Any discomfort or pain (usually in the upper abdomen), feeling bloated and full after only a tiny amount of food, inadequate appetite, sickness or vomiting stools that are dark or tar-colored, Low blood counts and exhaustion can be brought on by bleeding ulcers. This review HP Infection in Human Gastrointestinal Cancer Diagnosis and Treatment Control.

H. pylori infection inthe Stomach Cancer of the human

When the HP Microorganism transferred in intestinal of the human being so therefore the infection caused of the ulcer cancer. Furthermore, a lot of difficulty in human abdominal just like pain, vomiting, nausea, bleeding, lack of appetite etc.

[47] The 3rdfurthermost common cancer-related cause of death worldwide is stomach cancer. This review's objective is to synthesize the various factors that lead to the gradual development of normal stomach mucosa into gastric cancer. With the aid of this evaluation, professionals are better able to recognize infected people who are at a high risk of developing gastrointestinal cancer and carry out the required tests and treatments.

[48]This review will focus on the most important cellular adaptive mechanisms activated by H. pylori infection, such as endoplasmic reticulum stress and the unfolded protein response, autophagy, oxidative stress, and inflammation, followed by a discussion of how these elements may contribute to the development of a precancerous lesion. In order to open up new therapeutic options for non-invasive risk control in gastric cancer, this review will also illuminate how these systems may be used as pharmaceutical targets.

[49]Several significant questions regarding H. pylori's connection to stomach cancer need to be resolved. This article focuses on three of them: (1) the reason why H. pylori infection, which causes both gastric and duodenal inflammation, is only associated with gastric cancer.

[50] The two main risk factors for gastrointestinal cancer are infection with HP and a family history of the disease. It is unknown if H. pylori treatment can lower the risk of stomach cancer in people who have a history of the disease in first-degree relatives. Treatment for H. pylori eradication decreased the risk of gastrointestinal cancer in those with H. pylori infection who had a family history of the disease in first-degree relatives.

[51] HP induced stomach cancer appears to include multiple processes, making this route of carcinogenesis a very challenging procedure. However, there are still a lot of aspects of this tumorigenesis that need to be understood and explored.

[52]The 2nd leading cause of cancer-related fatalities global is stomach cancer. The majority of stomach malignancies are inflammatory tumours brought on by HP infection. In addition, HP itself has been related to neoplastic transformation and genetic instability due to epigenetic alterations and DNA damage.

H. pylori transmission to the human beings

H.pylori transmitted to the person to a person through vomit and saliva stool. *H.pylori* may be spread contaminated water and food etc.

[53] However, there is insufficient proof that flies that have come into touch with human faeces containing *H. pylori* can transfer the infection to people. However, the theory is intriguing because flies are known to spread numerous other contagious diseases. To stop the spread of H. pylori, it is critical to understand its epidemiology and route of transmission. This is especially true in regions with high rates of gastrointestinal lymphoma, stomach cancer, and stomach ulcers.

[54]Although the mode of transmission is not yet known, it is likely that the disease will spread from person to person, particularly within the same family, though environmental contamination is also a possibility. A successful eradication therapy almost never results in reinfection, and eradication without a precise therapeutic regimen is extremely uncommon. If there are infected family members, the likelihood of reinfection will rise.

[55]Although there is a chance of transmission through an external source, such as the water supply, illness is most likely spread from person to person. There have been arguments made in favor of and against oral-oral, faecal-oral, and gastric-oral transferred.

[56]In the recent study, we assess if HP is present in the stomachs of cows, sheep, and goats, identify the virulence factors for the bacteria, and then compare the virulence factors for humans and animals to determine whether HP could be transferred from these animals to humans. Our observations imply that sheep may operate as a reservoir for HP and in some ways share the ancestral host for the bacteria with human given the significant sequence homology between DNA of HP isolated from sheep and human.

9. Conclusion

H. pylori (HP) infection is still the most prevalent and persistent bacterial diseases in the world, making a precise diagnosis of the infection crucial. After receiving therapy for HP infection, there are numerous options for diagnosing infection and determining eradication. Various therapies are also employed as forms of treatment. The clinical state of the patient, the frequency of infection, and the frequency of clarithromycin resistance are just a few of the variables that must be taken into consideration when choosing the appropriate diagnostic approach and treatments for each patient. HP may not be the sole causes of these conditions, however, 70% to 90% of it are caused by the organism. Since the mode of transmission remained oral-oral and fecal-oral, it is therefore imperative to observe environmental cleanness and equally ensured that municipal water and food are safe before consumption.

References

1. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: treatment of *Helicobacter pylori* infection. Official journal of the American College of Gastroenterology| ACG, 112(2), 212-239.
2. Fallone, C. A., Chiba, N., van Zanten, S. V., Fischbach, L., Gisbert, J. P., Hunt, R. H., ... & Marshall, J. K. (2016). The Toronto consensus for the treatment of *Helicobacter pylori* infection in adults. Gastroenterology, 151(1), 51-69.
3. Butcher, G. P. (2003). Gastroenterology: an illustrated colour text. Elsevier Health Sciences.
4. *Helicobacter pylori* – Chapter 3. wwwnc.cdc.gov (Report). Travelers' Health. Vol. 2016 Yellow Book. Center for Disease Control. 9 June 2015. Retrieved 25 April 2017.
5. Alfarouk, K. O., Adil, H. H. B., Ahmed, N. A., AbdelRahman, M. R., Abdel, K. M., Sari, T. S. A., ... & Salvador, H. (2019). *Helicobacter pylori* the possible role of in gastric cancer and its management. Front Oncol, 9, 75.
6. Hooi, James KY, Wan Ying Lai, Wee Khoon Ng, Michael MY Suen, Fox E. Underwood, Divine Tanyingoh, Peter Malfertheiner et al. "Grant Support: Nil." (2017).
7. Yamaoka Y (2008). *Helicobacter pylori:* Molecular Genetics and Cellular Biology. Caister Academic Press. ISBN 978-1-904455-31-8.
8. Brown, L. M. (2000). *Helicobacter pylori:* epidemiology and routes of transmission. Epidemiologic reviews, 22(2), 283-297.
9. Marshall, C., Baller, J., & Stokes, S. (2009). COMMENTS OF.
10. Marshall, C., Baller, J., & Stokes, S. (2009). COMMENTS OF.
11. Pooja, V., Susmitha, K., Venkatesh, P., Kalarini, D. H., & Prema, R. A Literature Review on *Helicobacter pylori* Management.
12. Nocturne, G., Pontarini, E., Bombardieri, M., & Mariette, X. (2021). Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. Rheumatology, 60(8), 3513-3521.
13. Abbas, H., Niazi, M., & Makker, J. (2017). Mucosa-associated lymphoid tissue (MALT) lymphoma of the colon: a case report and a literature review. The American Journal of Case Reports, 18, 491.
14. Paydas, S. (2015). Helicobacter pylori eradication in gastric diffuse large B cell lymphoma. World Journal of Gastroenterology: WJG, 21(13), 3773.
15. Blaser, M. J. (2006). 'Who are we?'EMBO reports. Wiley, 7(10), 956-960.
16. Laird-Fick, H. S., Saini, S., & Hillard, J. R. (2016). Gastric adenocarcinoma: the role of *Helicobacter pylori* in pathogenesis and prevention efforts. Postgraduate Medical Journal, 92(1090), 471-477.
17. Salama, N. R., Hartung, M. L., & Müller, A. (2013). Life in the human stomach: persistence strategies of the bacterial pathogen *Helicobacter pylori*. Nature Reviews Microbiology, 11(6), 385-399.
18. Gravina, A. G., Zagari, R. M., De Musis, C., Romano, L., Loguercio, C., & Romano, M. (2018). *Helicobacter pylori* and extragastric diseases: A review. World journal of gastroenterology, 24(29), 3204.
19. Bravo, D., Hoare, A., Soto, C., Valenzuela, M. A., & Quest, A. F. (2018). *Helicobacter pylori* in human health and disease: Mechanisms for local gastric and systemic effects. World journal of gastroenterology, 24(28), 3071.

20. Ackerman, J. (2012). The ultimate social network. Scientific American, 306(6), 36-43.
21. Minalyan, A., Gabrielyan, L., Scott, D., Jacobs, J., & Pisegna, J. R. (2017). The gastric and intestinal microbiome: role of proton pump inhibitors. Current gastroenterology reports, 19(8), 1-10.
22. Selgrad, M., & Malfertheiner, P. (2008). New strategies for Helicobacter pylori eradication. Current opinion in pharmacology, 8(5), 593-597.
23. Blanchard TG, Nedrud JG (2010). "9. *Helicobacter pylori* Vaccines". In Sutton P, Mitchell H (eds.). Helicobacter pylori in the 21st Century. CABI. pp. 167–189. ISBN 978-1-84593-594-8. Retrieved 7 August 2013.
24. Kabir, S. (2007). The current status of *Helicobacter pylori* vaccines: a review. Helicobacter, 12(2), 89-102.
25. de Vries, R., Klok, R. M., Brouwers, J. R., & Postma, M. J. (2009). Cost-effectiveness of a potential future *Helicobacter pylori* vaccine in the Netherlands: the impact of varying the discount rate for health. Vaccine, 27(6), 846-852.
26. Rupnow, M. F., Chang, A. H., Shachter, R. D., Owens, D. K., & Parsonnet, J. (2009). Cost-effectiveness of a potential prophylactic *Helicobacter pylori* vaccine in the United States. The Journal of infectious diseases, 200(8), 1311-1317.
27. Sutton, P., & Boag, J. M. (2019). Status of vaccine research and development for *Helicobacter pylori*. Vaccine, 37(50), 7295-7299.
28. Tsukamoto, T., Nakagawa, M., Kiriyama, Y., Toyoda, T., & Cao, X. (2017). Prevention of gastric cancer: eradication of *Helicobacter pylori* and beyond. International journal of molecular sciences, 18(8), 1699.
29. Burkitt, M. D., Duckworth, C. A., Williams, J. M., & Pritchard, D. M. (2017). *Helicobacter pylori*- induced gastric pathology: insights from in vivo and ex vivo models. Disease models & mechanisms, 10(2), 89-104.
30. Fortunato, F., Bürgers, H., Bergmann, F., Rieger, P., Büchler, M. W., Kroemer, G., & Werner, J. (2009). Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology, 137(1), 350-360.
31. Li, L., & Yu, C. (2019). Helicobacter pylori infection following endoscopic resection of early gastric cancer. BioMed Research International, 2019.
32. Lamont, J. T. Patient education: *Helicobacter pylori* infection and treatment (Beyond the Basics).
33. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: treatment of *Helicobacter pylori* infection. *Official journal of the American College of Gastroenterology| ACG*, *112*(2), 212-239.
34. Fallone, C. A., Chiba, N., van Zanten, S. V., Fischbach, L., Gisbert, J. P., Hunt, R. H., ... & Marshall, J. K. (2016). The Toronto consensus for the treatment of *Helicobacter pylori* infection in adults. *Gastroenterology*, *151*(1), 51-69.
35. Malfertheiner, P., Megraud, F., O'morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., ... & El-Omar, E. M. (2017). Management of *Helicobacter pylori* infection—the Maastricht V/Florence consensus report. *Gut*, *66*(1), 6-30.
36. Megraud, F. (1995). Transmission of *Helicobacter pylori*: faecal-oral versus oral-oral route. *Alimentary pharmacology & therapeutics*, *9*, 85-91.

37. Cave, D. R. (1996). Transmission and epidemiology of *Helicobacter pylori*. *The American journal of medicine*, *100*, 12S-18S.
38. Delport, W., & van der Merwe, S. W. (2007). The transmission of *Helicobacter pylori:* the effects of analysis method and study population on inference. *Best practice & research Clinical gastroenterology*, *21*(2), 215-236.
39. De Francesco, V., Giorgio, F., Hassan, C., Manes, G., Vannella, L., Panella, C., ... & Zullo, A. (2010). Worldwide *H. pylori* antibiotic resistance: a systematic. *J Gastrointestin Liver Dis*, *19*(4), 409-414.
40. Mégraud, F. (2004). H pylori antibiotic resistance: prevalence, importance, and advances in testing. *Gut*, *53*(9), 1374-1384.
41. Kato, M., & Asaka, M. (2010). Recent knowledge of the relationship between *Helicobacter pylori* and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. *Japanese journal of clinical oncology*, *40*(9), 828-837.
42. Lee, Y. C., Dore, M. P., & Graham, D. Y. (2022). Diagnosis and treatment of *Helicobacter pylori* infection. *Annu Rev Med*, *73*, 4-1.
43. Liu, T. W., Ho, C. W., Huang, H. H., Chang, S. M., Popat, S. D., Wang, Y. T., ... & Lin, C. H. (2009). Role for α-l-fucosidase in the control of *Helicobacter pylori*-infected gastric cancer cells. *Proceedings of the National Academy of Sciences*, *106*(34), 14581-14586.
44. Parsonnet, J. (1993). *Helicobacter pylori* and gastric cancer. *Gastroenterology Clinics of North America*, *22*(1), 89-104.
45. Du, Y., Zhu, H., Liu, J., Li, J., Chang, X., Zhou, L., ... & Li, Z. (2020). Consensus on eradication of *Helicobacter pylori* and prevention and control of gastric cancer in China (2019, Shanghai). *Journal of gastroenterology and hepatology*, *35*(4), 624-629.
46. Bytzer, P., Dahlerup, J. F., Eriksen, J. R., Jarbøl, D. E., Rosenstock, S., & Wildt, S. (2011). Diagnosis and treatment of *Helicobacter pylori* infection. *Dan Med Bull*, *58*(4), C4271.
47. Ishaq, S., & Nunn, L. (2015). *Helicobacter pylori* and gastric cancer: a state of the art review. *Gastroenterology and hepatology from bed to bench*, *8*(Suppl1), S6.
48. Díaz, P., Valenzuela Valderrama, M., Bravo, J., & Quest, A. F. (2018). *Helicobacter pylori* and gastric cancer: adaptive cellular mechanisms involved in disease progression. *Frontiers in microbiology*, *9*, 5.
49. Mentis, A. F. A., Boziki, M., Grigoriadis, N., & Papavassiliou, A. G. (2019). *Helicobacter pylori* infection and gastric cancer biology: tempering a double-edged sword. *Cellular and Molecular Life Sciences*, *76*(13), 2477-2486.
50. Choi, I. J., Kim, C. G., Lee, J. Y., Kim, Y. I., Kook, M. C., Park, B., & Joo, J. (2020). Family history of gastric cancer and *Helicobacter pylori* treatment. *New England Journal of Medicine*, *382*(5), 427-436.
51. Zhang, X. Y., Zhang, P. Y., & Aboul-Soud, M. A. (2017). From inflammation to gastric cancer: Role of *Helicobacter pylori*. *Oncology letters*, *13*(2), 543-548.
52. Zhang, W., Lu, H., & Graham, D. Y. (2014). An update on *Helicobacter pylori* as the cause of gastric cancer. *Gastrointestinal tumors*, *1*(3), 155-165.
53. Brown, L. M. (2000). *Helicobacter pylori:* epidemiology and routes of transmission. *Epidemiologic reviews*, *22*(2), 283-297.
54. Stefano, K., Marco, M., Federica, G., Laura, B., Barbara, B., Gioacchino, L., & Gian, L. D. A. (2018). *Helicobacter pylori*, transmission routes and recurrence of infection: state of the art. *Acta Bio Medica: Atenei Parmensis*, *89*(Suppl 8), 72.

55. Goodman, K. J., & Correa, P. (1995). The transmission of *Helicobacter pylori*. A critical review of the evidence. *International Journal of Epidemiology*, *24*(5), 875-887.
56. Momtaz, H., Dabiri, H., Souod, N., & Gholami, M. (2014). Study of *Helicobacter pylori* genotype status in cows, sheep, goats and human beings. *BMC gastroenterology*, *14*(1), 1-7.

Access this Article in Online	
	Website: www.ijarbs.com
Quick Response Code	Subject: Microbiology
DOI:10.22192/ijarbs.2022.09.07.011	

How to cite this article:
Waqar Ahmad Khan, Shahid Alishah. (2022). *H. pylori* Infection in human Gastrointestinal Cancer Diagnosis and Treatment Control: A review. Int. J. Adv. Res. Biol. Sci. 9(7): 108-119.
DOI: http://dx.doi.org/10.22192/ijarbs.2022.09.07.011